Embryo Aneuploidies and Morphokinetics in Ovarian Stimulated and Non Stimulated IVF Cycles (AMOS)

Embryo Aneuploidies and Morphokinetics in Ovarian Stimulated and Non Stimulated Cycles. An Intrapatient Comparison Using Next Generation Sequencing in Biopsy of Blastocysts and Time Lapse Evaluation.

The purpose of this study is to compare the number of euploid embryos obtained per metaphase II oocyte in unstimulated (modified natural cycles) and stimulated IVF cycles.

Study Overview

Status

Terminated

Conditions

Detailed Description

Effects of ovarian stimulation on human embryo quality is still a subject of study. When natural and stimulated cycles have been compared, no differences have been observed in terms of embryo cleavage capacity, oocyte and embryo aneuploidy rate or incidence of aneuploidy in aborted foetuses. When mild and conventional doses of gonadotropins have been compared, a higher proportion of good morphological quality embryos are observed in the former. On the contrary, we showed that ovarian stimulation does not increase significantly the embryo aneuploidy rate in IVF derived human embryos when unstimulated and stimulated cycles were compared in oocyte donors. In this study, we want to compare the embryo aneuploidy rate between unstimulated and stimulated cycles in infertile patients, subjected to both IVF cycles with blastocyst biopsy and NGS-PGS. A comparison of the morphokinetics will also be performed.

Study Type

Observational

Enrollment (Actual)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Valencia, Spain, 46015
        • IVI Valencia
      • Valencia, Spain, 46015
        • Instituto Valenciano de Infertilidad Spain
      • Valencia, Spain, 46003
        • IVI Valencia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 38 years (Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Women undergoing In Vitro Fertilization treatment

Description

Inclusion Criteria:

  • Women
  • 30-38 years old (inclusive)
  • with regular menstrual cycles (25-35 days)
  • AntiMülleriana Hormone >5 pmol/L.
  • Undergoing IVF treatment

Exclusion Criteria:

  • BMI >30 kg/m2
  • repeated miscarriages
  • implantation failure
  • uterine or adnexal pathology
  • Unable to be treated with gonadotrophins for the ovarian hyperstimulation
  • history of low response to ovarian hyperstimulation
  • participation in another study with PGS for monogenic pathology
  • Cryptozoospermia in male partner

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Natural Cycle
The patient will not undergo hyperstimulation rather a natural cycle
Stimulated Cycle
The 80 patients will undergo hyperstimulation cycle as per the clinical practice planned for the patient.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of the number of euploid embryos from Metaphase II oocytes in different cohorts of embryos.
Time Frame: 30 days
Number of metaphase II oocyte per euploid embryo in unstimulated and stimulated cycles.
30 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of embryo aneuploidies in two cohorts of embryos.
Time Frame: 30 days
Incidence of embryo aneuploidies between the unstimulated and stimulated cycle in the same patient
30 days
Morphokinetic evaluation of embryos in two different cohorts of embryos.
Time Frame: 30 days
Morphokinetic evaluation of the embryos obtained in an unstimulated and stimulated cycle
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 21, 2017

Primary Completion (Actual)

April 7, 2020

Study Completion (Actual)

July 3, 2020

Study Registration Dates

First Submitted

April 10, 2017

First Submitted That Met QC Criteria

April 20, 2017

First Posted (Actual)

April 25, 2017

Study Record Updates

Last Update Posted (Actual)

July 23, 2020

Last Update Submitted That Met QC Criteria

July 21, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1703-VLC-021-EL

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Euploid Embryos

3
Subscribe